Clinical data
ATC code C07AB01 (WHO)
CAS Number 6673-35-4 YesY
PubChem (CID) 4883
DrugBank DB01297 YesY
ChemSpider 4715 YesY
KEGG D05587 N
ChEBI CHEBI:258351 YesY
ECHA InfoCard 100.027.012
Chemical and physical data
Formula C14H22N2O3
Molar mass 266.336 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Practolol (Eraldin, Dalzic, Praktol, Cardiol, Pralon, Cordialina, Eraldina, Teranol) is a selective beta blocker that has been used in the emergency treatment of cardiac arrhythmias. Practolol is no longer used as it is highly toxic despite the similarity of its chemical formula to propranolol. After its introduction, keratoconjunctivitis sicca, conjunctival scarring, fibrosis, metaplasia, and shrinkage developed in 27 patients as an adverse reaction to practolol. Rashes, nasal and mucosal ulceration, fibrous or plastic peritonitis, pleurisy, cochlear damage, and secretory otitis media also occurred in some cases. Three patients suffered profound visual loss though most retained good vision. Symptoms and signs improved on withdrawal of the drug, but reduction of tear secretion persisted in most patients. (British Medical Journal, March 15, 1975)


The compound was studied by scientists at the Research Department of the ICI Pharmaceuticals Division in Alderley Park with physiologists at the University of Leeds in the early 1970s when it was known as compound ICI 66082; they utilised dogs, cats and rats in their investigations. Earlier research had also been carried out as early as 1967 on this and similar molecules by other research teams also with ICI.[1] [2]

Side effects

Side effects are similar to those of other beta blockers, such as bronchoconstriction, cardiac failure, cold extremities, fatigue and depression, hypoglycaemia.[3]

Furthermore, chronic use of practolol may cause oculomucocutaneous syndrome,[3] a severe syndrome whose signs include conjunctivitis sicca and psoriasiform rashes, otitis and sclerosing serositis. This syndrome has not been observed with other such beta blockers.[4]


This drug has been withdrawn from the market in India.[5]


NB: Obviously, part of the structure is based on paracetamol.

Practolol synthesis:[6] Howe, Smith, NL 6512676 ; eidem, U.S. Patent 3,408,387 (1966, 1968, to I.C.I.).

A synthesis is available which relates the absolute configuration of the more potent optical isomer to (+)-lactic acid. The glycerol derivative (2) is available from D-mannitol and retains optical activity as the two 1° alcohol functions are differentially protected. Displacement with sodium p-acetamidophenoxide (1) gives 3 which is deprotected with dilute acid, the primary alcohol function is selectively reacted with one molar equivalent of tosyl chloride and pyridine, then treated with NaOH in dimethylsulfoxide to yield 3. Epoxide opening with isopropylamine leads to optically active prolactolol (4).


  1. BARRETT, A.M.; et al. (June 1973). "A new type of cardioselective adrenoceptive blocking drug". Br J Pharmacol. 48 (2): 340P. PMC 1776195Freely accessible. PMID 4147428.
  2. DUNLOP, D.; et al. (January 1968). "SELECTIVE BLOCKADE OF ADRENOCEPTIVE BETA RECEPTORS IN THE HEART drug" (PDF). Br. J. Pharmac. Chemother. 32 (1): 201–218. doi:10.1111/j.1476-5381.1968.tb00444.x. PMC 1570292Freely accessible. PMID 4384337. Retrieved 15 June 2015.
  3. 1 2 Rod Flower; Humphrey P. Rang; Maureen M. Dale; Ritter, James M. (2007). Rang & Dale's pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-06911-5.
  4. > Nadolol Retrieved on July, 2010.
  5. "Drugs banned in India". Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India. Archived from the original on 2015-02-21. Retrieved 2013-09-17.
  6. Danilewicz, J. C.; Kemp, J. E. G. (1973). "Absolute configuration by asymmetric synthesis of (+)-1-(4-acetamidophenoxy)-3-(isopropylamino)propan-2-ol) (practolol)". Journal of Medicinal Chemistry. 16 (2): 168. doi:10.1021/jm00260a020. PMID 4405110.
Scientific information / studies
General information

This article is issued from Wikipedia - version of the 9/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.